Slide 1: First Quarter 2018: Trusted by the Life Sciences Industry
First Quarter 2018 Trusted by the Life Sciences Industry 1
Slide 2: Safe Harbor – Forward Looking Statements
Safe Harbor – Forward Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties. Such forward-looking statements include statements regarding attempts to identify new strategic opportunities which may include a strategic transaction, plans
Slide 3: Financial Highlights: Q1-2018
Financial Highlights: Q1-2018 Revenue Biopharma Supporting revenue 31 Phase III $4.0M 236 clinical trials trials up 48.3% up 62.3% Reproductive Gross Margin 24 biopharma clients Medicine added during the quarter 54.3% up 20.1% up 8.1PP Strong embedded growth Opex up 31.8% in support of with existing
Slide 4: Novartis – Kymriah Ramp Continues
Novartis – Kymriah™ Ramp Continues 35 certified treatment centers $12 million Q1 2018 revenue for Novartis Manufactured for over 300 patients in 11 countries Over 500 employees supporting Kymriah™ 4
Slide 5: Gilead – Yescarta ramp builds
Gilead – Yescarta ramp builds • Yescarta approved in U.S. in October 2017 • European approval anticipated in Q3 2018 • 40 cancer centers authorized as of April 30, 2018 – Expanding number of authorized centers and by mid-2018 reaching institutions responsible for treating ~80% of eligible patients •
Slide 6: Clinical Trials Drive Revenue Growth in Biopharma
Clinical Trials Drive Revenue Growth in Biopharma 22 new clinical trials (net) added in Q1-2018; 97 clinical trials (net) added since Q1-2017; 31 Phase III 236 31 100 105 6
Slide 7: Adaptive Cellular Therapy :: Immuno-Oncology Landscape
Adaptive Cellular Therapy :: Immuno-Oncology Landscape Source – Wells Fargo Securities Conference, November 2017 7
Slide 8: Primary Target Market: Regenerative Therapy
Primary Target Market: Regenerative Therapy Ph. I: 320 Inflection point: Commercialization has begun (261 in 2016) Novartis’ CAR-T drug, Kymriah™, 959 (a) (192 in 2015) Ph. II: 549 approved in August 2017 and Gilead/Kite therapy, Yescarta™, approved in October 2017 (376 in 2016) At least 5-7 additio
Slide 9: Cryoport Express C3 Shipper for Clients Requiring Reliable 2-8°C Logistics Solutions
Cryoport Express® C3TM Shipper for Clients Requiring Reliable 2-8°C Logistics Solutions The introduction of Cryoport Express® C3 TM means that Cryoport supports the entire logistics continuum for regenerative medicine clinical and commercial programs The Cryoport Express® C3TM Solution seamlessly in
Slide 10: Cryoport's Continuous Vigilance to Minimize Risk and Maximize Success
Cryoport’s Continuous Vigilance to Minimize Risk and Maximize Success CHAIN of CUSTODY CHAIN of CONDITION CHAIN of IDENTITY CHAIN of COMPLIANCE Traceability of each Traceability of the Environmental Traceability of the Identity Traceability of the Equipment Client’s or Controls of each Client’s of e
Slide 11: CryoStork for Reproductive Medicine
CryoStork℠ for Reproductive Medicine 11
Slide 12: Quarterly Revenue Trends
Quarterly Revenue Trends Continued quarterly revenue growth fueled by revenue expansion from existing clients and new client acquisition $4.0M $3.3M $2.9M $3.0M $2.7M Q1-2018 over Q1-2017 growth: 48.3% Sequential growth: 21.1% 12
Slide 13: Revenue Trends
Revenue Trends Biopharma growth continues to be driven by ramp in clinical trials supported and commencement of revenue from the support of commercials therapy launches Q1-2018 over Q1-2017 growth: +62.3% +20.1% -12.1% 13
Slide 14: Cryoport has a Scalable Business Model
Cryoport has a Scalable Business Model Continuing double-digit growth in revenue, year-over-year and sequentially, further increases gross margin Net revenue for Q1-2018 vs. prior year ($mm) Gross margin % for Q1-2018 vs. prior year $5.0 60.0% + 8.1PP 54.3% + 48.3% $4.0 $4.0 50.0% 46.2% $2.7 40.0% $
Slide 15: Review
Review Leading temperature-controlled logistics solutions provider for the life sciences industry with a focus on Business description the regenerative medicine market (CAR-T) Clients Pharmaceutical and biotechnology companies (Novartis, Gilead/Kite(a), TiGenix, etc.) Markets Biopharma, Reproductive
Slide 16: Thank you!
Science. Logistics. Certainty. Thank you! 16